Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PAVmed (PAVM) EPS (Weighted Average and Diluted) (2022 - 2025)

PAVmed (PAVM) has 4 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.29 in Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) changed N/A year-over-year to -$0.29; the TTM value through Sep 2025 reached -$0.45, changed N/A, while the annual FY2024 figure was $0.5, 105.46% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.29 in Q3 2025 per PAVM's latest filing, down from -$0.21 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.34 in Q1 2025 and bottomed at -$14.25 in Q4 2022.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$2.69, with a median of -$1.16 recorded in 2024.
  • Peak YoY movement for EPS (Weighted Average and Diluted): tumbled 720.69% in 2023, then surged 112.98% in 2025.
  • A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$14.25 in 2022, then soared by 39.09% to -$8.68 in 2023, then skyrocketed by 96.66% to -$0.29 in 2024, then rose by 0.0% to -$0.29 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.29 in Q3 2025, -$0.21 in Q2 2025, and $0.34 in Q1 2025.